| Literature DB >> 30669532 |
Artium Belet1, Cédric Wolfs2, Julien G Mahy3, Dirk Poelman4, Christelle Vreuls5, Nathalie Gillard6, Stéphanie D Lambert7.
Abstract
A screening study on seven photocatalysts was performed to identify the best candidate for pharmaceutical products degradation in water. Photocatalysts were deposited as thin films through a sol-gel process and subsequent dip-coating on glass slides. The efficiency of each photocatalyst was assessed through the degradation of methylene blue first, and then, through the degradation of 15 different pharmaceutical products. Two main types of synthesis methods were considered: aqueous syntheses, where the reaction takes place in water, and organic syntheses, where reactions take place in an organic solvent and only a stoichiometric amount of water is added to the reaction medium. Photocatalysts synthesized via aqueous sol-gel routes showed relatively lower degradation efficiencies; however, the organic route required a calcination step at high temperature to form the photoactive crystalline phase, while the aqueous route did not. The best performances for the degradation of pharmaceuticals arose when Evonik P25 and silver nanoparticles were added to TiO₂, which was synthesized using an organic solvent. In the case of methylene blue degradation, TiO₂ modified with Evonik P25 and TiO₂ doped with MnO₂ nanoparticles were the two best candidates.Entities:
Keywords: TiO2; pharmaceutical products; photocatalysis; sol-gel process; thin films
Year: 2019 PMID: 30669532 PMCID: PMC6358872 DOI: 10.3390/nano9010126
Source DB: PubMed Journal: Nanomaterials (Basel) ISSN: 2079-4991 Impact factor: 5.076
Characterization of the coating by ICP-AES, profilometry, and X-ray diffraction.
| Sample | Theoretical Dopant Content (wt%) | Actual Dopant Content (wt%) | Deposited Layers | Coating Thickness (nm) a | Absolute Roughness (nm) a | Scherrer Crystallite Size (nm) |
|---|---|---|---|---|---|---|
| TiO2 org (a) | - b | - b | 2 | 57 ± 15 | 0.8 ± 0.3 | 17 |
| TiO2 + Ag | 1 | 0.92 | 2 | 66 ± 3 | 2.0 ± 0.2 | 109 |
| TiO2 + P25 (a) | - b | - b | 3 | 97 ± 25 | 155 ± 33 | 18 |
| TiO2 + MnO2 | 5.42 | 3.49 | 2 | 89 ± 23 | 29.4 ± 8.4 | 18 |
| ZnO (b) | - b | - b | 2 | 56 ± 14 | 2.6 ± 0.4 | 80 |
| TiO2 aq (a) | - b | - b | 2 | 57 ± 10 | 1.5 ± 1.0 | - c |
| TiO2 + Zn2+ | 0.41 | 0.47 | 4 | 20 ± 4 | 0.7 ± 0.4 | - c |
- a: indicated with the standard deviation of three measurements; - b: irrelevant; - c: signal/noise ratio too low to measure.
Figure 1Grazing incidence diffractograms of all samples. ■ TiO2 org; ◆ TiO2 + Ag; ▲TiO2 + P25; ✕ TiO2 + MnO2; • TiO2 aq; ♥ TiO2 + Zn2+; ♣ Anatase (from database RRUFF R060277); ♠ ZnO; ☼ Zincite (from database RRUFF R050492).
Band gap energies calculated by the Kubelka–Munk method from diffuse reflectance measurements on powders for the different allowed electronic transitions.
| Sample | Direct Band Gap Energy (eV) | Indirect Band Gap Energy (eV) |
|---|---|---|
| TiO2 org | 3.14 | 2.95 |
| TiO2 + Ag | 3.14 | 2.82 |
| TiO2 + P25 | 3.13 | 2.93 |
| TiO2 + MnO2 | - a | - a |
| ZnO | - b | 3.04 |
| TiO2 aq | 3.24 | 2.87 |
| TiO2 + Zn2+ | 3.29 | 2.91 |
- a: powder too dark to be measured; - b: not applicable.
Contributions of the different catalysts on the degradation of methylene blue and different pharmaceutical products after 4 h, minus the effects of UVc only degradation and adsorption.
| Sample | dMB (%) | dlorazepam (%) | dtramadol (%) | dalprazolam (%) | dibuprofen (%) | dmetformin (%) | dPP a (%) |
|---|---|---|---|---|---|---|---|
| TiO2 org | 24.4 | 33.4 | 13.7 | 6.7 | 29.7 | 21.9 | 21.1 |
| TiO2 + Ag | 29.1 | 30.4 | 13.7 | 40.1 | 11.9 | 51.1 | 29.4 |
| TiO2 + P25 | 58.5 | 34.7 | 19.2 | 13.1 | 49.5 | 50.0 | 33.3 |
| TiO2 + MnO2 | 51.7 | 30.8 | 17.0 | 5.7 | 27.4 | 27.0 | 21.6 |
| ZnO | 36.5 | 7.0 | 14.2 | <1 | 19.8 | <1 | 8.2 |
| TiO2 aq | 37.1 | 31.4 | 4.0 | <1 | 14.1 | <1 | 9.9 |
| TiO2 + Zn2+ | 13.7 | 15.9 | <1 | <1 | <1 | 14.0 | 6.0 |
a: grouping all the pharmaceutical products (PP) as one single type of chemical.
Toxicity of a solution of the 15 pharmaceutical products concentrated at 50 µg/L after the different treatment steps.
| Solution | Untreated | Treated with O3 | Treated with O3 + UV | Treated with O3 + UV + Photocatalysis |
|---|---|---|---|---|
| Toxicity | 1.32 | 1.33 | 1.33 | 1.19 |